Pfizer, BioNTech complete submission to Europe drug regulator for updated COVID shot – Seeking Alpha

Vaccination Clinic Administers Booster Shots In California

Justin Sullivan

Pfizer (NYSE:PFE) and German partner BioNTech (NASDAQ:BNTX) on Friday said they had completed a submission to Europe’s drug regulator for a booster dose of their Omicron-subvariant adapted bivalent COVID-19 vaccine.

The submission to the European Medicines Agency (EMA) comes just days after the companies applied for an emergency use approval of the bivalent shot to the U.S. FDA.

All components of the bivalent vaccine are unchanged from the original Comirnaty shot, except for the addition to the mRNA of the Omicron BA.4/BA.5 spike protein sequence, the companies said in a statement.

Pfizer (PFE) and BioNTech (BNTX) had previously also filed an application with the EMA for an Omicron BA.1 adapted vaccine in July, which is currently under review by the agency.

Both the Omicron BA.1-adapted and BA.4/BA.5 adapted boosters will be available as early as Sept. if approvals are received, PFE and BNTX said.

The U.S. and Europe are gearing up for COVID vaccination campaigns for the fall and winter, in which the BA.4/BA.5 subvariants are expected to be the dominant circulating strains.

PFE stock -0.5% to $47.65 in morning trading, while U.S.-listed shares of BNTX were 0.9% lower at $147.23.

Spread the love

Leave a Reply

Your email address will not be published.